3 findings
“Those with non-HDL-C level ≤100 mg/dL had median fatty plaque regression of 18.8% [IQR: 6.9, 30.8] compared to median progression of 9.0%”
Effects
1Coronary fatty plaque regression
upin humans1
1 study
Coronary fatty plaque regression
upin humans1
Non-HDL cholesterol ≤100 mg/dL improves coronary fatty plaque regression in humans (CAD with well-controlled hypertension on statin therapy (control group)) (median regression 18.8% vs 9.0% progression).
“Those with non-HDL-C level ≤100 mg/dL had median fatty plaque regression of 18.8% [IQR: 6.9, 30.8] compared to median progression of 9.0%”
Human trialCAD with well-controlled hypertension on statin therapy (control group)coronary artery30 monthsn = 53
AHA Scientific Sessions 2025 abstract
Associations
2Fibrinogen
upin humans1
1 study
Fibrinogen
upin humans1
Non-HDL cholesterol ≤100 mg/dL is associated with fibrinogen in humans (CAD with well-controlled hypertension on statin therapy (control group)) (p=0.005).
“Those with non-HDL-C level >100 mg/dL had significantly higher levels of inflammatory markers: neutrophil count (p=0.047) and fibrinogen level (p=0.005)”
Human trialCAD with well-controlled hypertension on statin therapy (control group)30 monthsn = 53
AHA Scientific Sessions 2025 abstract
Neutrophil count
upin humans1
1 study
Neutrophil count
upin humans1
Non-HDL cholesterol ≤100 mg/dL is associated with neutrophil count in humans (CAD with well-controlled hypertension on statin therapy (control group)) (p=0.047).
“Those with non-HDL-C level >100 mg/dL had significantly higher levels of inflammatory markers: neutrophil count (p=0.047) and fibrinogen level (p=0.005)”
Human trialCAD with well-controlled hypertension on statin therapy (control group)30 monthsn = 53
AHA Scientific Sessions 2025 abstract